Prognosis in Biological Technology

Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer

... tumor cell (CTC) count can accurately predict the prognosis and survival in patients with metastatic breast ... count of five or more could better predict the prognosis and survival in MBC patients. The ... therapeutic monitoring accurately predicted prognosis in MBC beyond metabolic response. FDG-PET/CT was ...

Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009

... with an important measure of a patient's disease prognosis to help them make more informed patient care ... for the past two years to regularly monitor the prognosis of his population of metastatic breast cancer ... to traditional imaging, to help me assess the prognosis of a patient and gauge her response to current ...

Glycominds Appoints Board of Directors Chairman

... we roll-out our innovative tests for autoimmune prognosis and the early detection of cancer in ... the potential to enhance autoimmune prognosis and the early detection of cancers. Glycominds is ... of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in ...

Data on WaferGen's SmartChip(TM) System to be Presented at 3rd Annual Rediscovering Biomarkers Conference

... provide physicians with new tools for determining accurate disease prognosis in patients, while also potentially providing drug developers with ... an examination of the impact the validated SNPs have on patients' disease prognosis and response to treatment. About the SmartChip Real-Time PCR ...

Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference

... Thursday, 12 March 2009 Poster 0072 The 70-gene MammaPrint prognosis Signature for Optimal Risk Stratification in Endocrine Responsive Breast ... 't Veer. Thursday, 12 March 2009 Poster 0074 Early prognosis Prediction: MammaPrint on Core-needle biopsies F. de Snoo, A. Glas, ...

Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer

... with the capability of detecting early-stage ovarian cancer, predicting prognosis and recurrence, and identifying women considered at high-risk for the ... with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this ....

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

... Overexpression of Pim-1 kinase has been shown to be a marker of poor prognosis in these tumors. A second Phase I/II study is being planned in patients ... in which Pim kinases are also overexpressed, and correlated with poor prognosis and drug resistance. "We are pleased to acknowledge FDA's ...

MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions

... today that data from two studies involving its MammaPrint(R) breast cancer prognosis test will be presented at the American Society of Clinical Oncology's ... was changed. The abstract (Implementation assessment of the 70-gene prognosis signature for breast cancer diagnostics) will be presented by Valesca ...

Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy

... 1" tumors should not be treated with chemotherapy because they have a good prognosis and are often chemo-insensitive. A key clinical issue is how to treat ... more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also ...

Clarient to Commercialize Novel Breast Cancer Profile

... that develops high-value molecular diagnostics for disease detection, prognosis and selection of appropriate therapy. Clarient's Insight Dx Breast ... commercialized to provide valuable cancer characterization information for prognosis and therapy selection for the major cancer types. "This new agreement ...

Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award

... trial in which specific predictive aspects of MammaPrint(R) breast cancer prognosis assay are further tested. Since inception in 1993 by Evelyn Lauder, the ... of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation ...

NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma

... we are in a unique position to advance the fields of cancer diagnosis, prognosis and therapeutics. This collaboration with NYU will give both organizations ... will help to more fully understand melanoma and subsequently the prognosis of melanoma patients." About microRNAs MicroRNAs (miRNAs) are a recently ...

Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate

... 5.7 million people in the United States, with 670,000 new cases diagnosed each year. Despite the treatment of heart failure with multiple drugs, the prognosis remains poor. There were over 1.1 million hospitalizations for heart failure in 2006 in the United States, with estimated direct and indirect costs ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... so called minimal residual disease (MRD). Various studies have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD. According to the EMEA, "orphan" medicinal products are intended for the diagnosis, prevention or treatment of ...

Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia

... which severely impairs the patient functional status and quality of life, and is associated with an increased cardiovascular mortality and morbidity. prognosis of critical limb ischemia is poor and no effective treatments have been established in patients who are not amenable for the traditional ...

DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research

... These genetic samples will allow us to further investigate the underlying genetic causes of breast cancer with the goal to improve diagnosis, assist prognosis and identify specific targets for therapeutic intervention. Participants will be enthusiastic about using Oragene•DNA to contribute a sample ...

LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit

... alpha protein is low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy. Enzon is currently conducting two Phase I studies, evaluating the HIF-1 alpha antagonist in different dosing schedules. ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... for safety and n=19 evaluable for efficacy). Adecatumumab is an antibody that targets EpCAM, a tumor antigen known to be associated with poor prognosis for breast cancer patients. Combining adecatumumab with docetaxel was feasible with clinically manageable diarrhea being the main toxicity at higher ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... PharmaMar SAU, Madrid, Spain; University of California Irvine Medical Center, Orange, CA Early hemoglobin decline and survival prognosis in epoetin alfa studies (Abstract 9625) General Poster Session, Monday June 1, 8:00 am to 12:00 pm, Level 2, West Hall C ...

Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)

... but the absence of symptoms and the lack of reliable diagnostic instruments for early detection of tumors contribute to the poor prognosis in patients. Direct visualization of the biliary system is not yet a standard tool for excluding malignancy in bile duct ...

FDA Clears Boston Scientific's SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System

... patients often not exhibiting symptoms until late in the disease process. As a result, the majority of patients with late-stage disease have a poor prognosis for survival. "Early detection is critical to improving outcomes in patients with pancreatic cancer, but the 'silent' nature of the disease -- ...

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models

... the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients. About Joseph F. Finn, Jr., C.P.A. Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & ...

Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors

... the activity of galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients. It is presently in Phase 2 clinical trials. The intellectual property, regulatory dossier, fixed assets and clinical inventory ...

Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting

... tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas ...

Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource

... for use at the point of care, it provides instant, user-friendly access to the latest information on evaluation, diagnosis, clinical management, prognosis and prevention. Dr. Goldmann brings a wealth of experience in the medical field. He is an internist and Associate Professor of Medicine at the ...

Optherion Announces Presentation at ARVO 2009 Annual Meeting

... the population distribution of genetic markers of AMD. This study assists us in completing the development of a genetic test that will inform prognosis and risk of AMD." About Optherion: Optherion, Inc. is a private innovative biotechnology company that is developing protein therapeutics and ...

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation

... A and B correspond to ER-positive breast cancers, we have always known that luminal A subtype patients are associated with a significantly better prognosis in breast cancer. Clarient's agreement to license FOXA1 from IURTC provides for another strong marker to help identify these luminal A subtypes." ...

The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure

... shown to reverse the disease and restore cardiac function. "Despite important therapeutic advances in pharmacologic and device therapies, the prognosis of patients with chronic heart failure remains extremely poor. Moreover, heart transplantation and the use of implantable assist devices are ...

Polycystic Kidney Disease Assay at Cornell University Uses Transgenomic's Surveyor Nuclease & WAVE Technology

... of using Transgenomic's Surveyor Nuclease technology for mutation scanning of PKD1 and PKD2 , two important genes used in the diagnosis and prognosis of autosomal dominant polycystic kidney disease (ADPKD). The assay showed 100% concordance with the current standard, DNA sequencing, but decreased ...

Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code

... new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to ...

TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity

... being the most prominent. Current treatments of Parkinson's Disease help to offset symptoms for a limited period of time, but do not alter the prognosis of the disease, which would require to stop the loss of nerve cells, a feat not accomplished in any neurodegenerative disorder to date. "LRRK2 ...

BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University

... therapy, determine the potential toxicity of therapeutic agents to patients who have or are likely to develop a specific disease, predict a patient's prognosis once a disease has been diagnosed and monitor a patient's disease progression or drug response. The company's patented technology platform is ...

WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institute's Quantitative PCR Conference

... and conditions. In turn, this critical genetic information may ultimately provide physicians with new tools for determining accurate disease prognosis in patients, while also potentially providing drug developers with information necessary for the creation of targeted therapeutics. About ...

KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure

... showed symptoms of insufficient heart function while at rest and were unable to carry out any form of physical activity without discomfort. The prognosis for patients with NYHA Class IV heart failure is very poor, with mortality rates as high as 74 percent within 6 months and 94 percent within 12 ...

Virginia Tech engineers investigate energy independent monitoring system for bridges

... to include the development of the energy harvesting system, the sensors themselves, and the data interpretation, damage assessment and health prognosis software. Inman said that as "the inventory of bridges continues to age, routine inspection practices will not be sufficient for bridge owners to ...

Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance

... along with other standard measures such as tumor size, Oncotype DX contributes independently to provide a more complete picture of prognosis for node-negative and node-positive patients treated with aromatase inhibitors. - An oral presentation suggesting that ...

International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"

... diagnosis and treatment of multiple myeloma and other plasma cell disorders. Not only does the use of Freelite considerably improve the assessment of prognosis in virtually every plasma cell disorder, it also increases the accuracy with which diseases can be monitored, thus improving the overall quality of ...

In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia

... and oncologists decisions along their complex therapeutic path. With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... so called minimal residual disease (MRD). Various reports have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD. Interim results for the ongoing phase 2 clinical trial of blinatumomab for ALL find the BiTE antibody was able to ...

Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium

... Location: Exhibit Hall D -- Friday, December 12, 2008, 7 a.m. - 9 a.m. Abstract #2066 Poster presentation (Poster Session II: prognosis and Response Predictions: Biomarkers -- Methods): "Quantitative gene expression analysis using Oncotype DX in ductal carcinoma in situ ...